Control of baseline cardiovascular risk factors in the SU-FOL-OM3 study cohort: does the localization of the arterial event matter?
OBJECTIVE
No data are currently available on the prevalence and control of cardiovascular (CV) risk factors in secondary prevention depending on the cardiac or cerebral localization of the ischemic disease. We investigated the prevalence and control of modifiable CV risk factors, as well as the determinants of CV risk factors' control and adequate treatment in a secondary prevention cohort, the SU-FOL-OM3 study cohort, to determine the role of the localization of the ischemic disease including events.


RESULTS
A total of 2491 patients were included in the study. The prevalence of all modifiable risk factors was high in both coronary heart disease and cerebrovascular disease (CVD) groups. Control of all risk factors and the presence of antiplatelet medication were noted in 29.6% of patients with coronary heart disease and 11% of patients with CVD. The cardiac localization of the including event was independently associated with the control of each of the risk factors studied (hypertension, low-density lipoprotein-cholesterol, smoking) and to the control of all risk factors present and prescription of antiplatelet therapy with an odds ratio (95% confidence interval) of 2.72 (1.97-3.75).


CONCLUSIONS
There is a need to improve the control of CV risk factors in secondary prevention patients. This is particularly crucial for patients with CVD.
Vesin
Claire
C
Paris Descartes University, Faculty of Medicine, AP-HP, Hôtel-Dieu Hospital, Diagnosis and Therapeutic Center, Paris, France.
Galan
Pilar
P
Gautier
Benoit
B
Czernichow
Sebastien
S
Hercberg
Serge
S
Blacher
Jacques
J
D000368:Aged; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D002545:Brain Ischemia / Q000209:etiology / Q000517:prevention & control / Q000628:therapy*; D016009:Chi-Square Distribution; D008078:Cholesterol, LDL / Q000097:blood; D015331:Cohort Studies; D003920:Diabetes Mellitus / Q000188:drug therapy; D019587:Dietary Supplements; D004311:Double-Blind Method; D015525:Fatty Acids, Omega-3 / Q000627:therapeutic use; D005260:Female; D005492:Folic Acid / Q000627:therapeutic use; D005602:France; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000209:etiology / Q000517:prevention & control / Q000628:therapy*; D016017:Odds Ratio; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D018570:Risk Assessment; D012307:Risk Factors; D055502:Secondary Prevention / Q000379:methods*; D016540:Smoking Cessation; D016896:Treatment Outcome; D014805:Vitamin B 12 / Q000627:therapeutic use; D025101:Vitamin B 6 / Q000627:therapeutic use
D000924:Anticholesteremic Agents; D000959:Antihypertensive Agents; D015415:Biomarkers; D008078:Cholesterol, LDL; D015525:Fatty Acids, Omega-3; D007004:Hypoglycemic Agents; D010975:Platelet Aggregation Inhibitors; D025101:Vitamin B 6; D005492:Folic Acid; D014805:Vitamin B 12